50% of women with breast cancer suffer through expensive and potentially lethal chemotherapy they don’t need. Digistain solves this problem by scanning biopsies in the infrared to measure the increase in cancerous DNA. We remove the guesswork from diagnosis.
Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024. The first abstract showcased head-to-head data from Charing
We’re excited to announce that Digistain® has partnered Deloitte to drive adoption across Europe! This collaboration marks a significant step toward making breast cancer risk
We’re thrilled to announce that Digistain® is now available to over 60% of UK private patients, with reimbursement available though Bupa, WPA Health Insurance &
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.